These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Efficient delivery of miR-122 to regulate cholesterol metabolism using a non-covalent peptide-based strategy. Wang L; Tang W; Yan S; Zhou L; Shen T; Huang X; Dou L; Wang M; Yu S; Li J Mol Med Rep; 2013 Nov; 8(5):1472-8. PubMed ID: 24065042 [TBL] [Abstract][Full Text] [Related]
49. LNA-modified oligonucleotides effectively drive intramolecular-stable hairpin to intermolecular-duplex state. Kaur H; Wengel J; Maiti S Biochem Biophys Res Commun; 2007 Jan; 352(1):118-22. PubMed ID: 17107660 [TBL] [Abstract][Full Text] [Related]
50. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944 [TBL] [Abstract][Full Text] [Related]
51. Silencing microRNA by interfering nanoparticles in mice. Su J; Baigude H; McCarroll J; Rana TM Nucleic Acids Res; 2011 Mar; 39(6):e38. PubMed ID: 21212128 [TBL] [Abstract][Full Text] [Related]
52. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583 [TBL] [Abstract][Full Text] [Related]
53. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. McLendon JM; Joshi SR; Sparks J; Matar M; Fewell JG; Abe K; Oka M; McMurtry IF; Gerthoffer WT J Control Release; 2015 Jul; 210():67-75. PubMed ID: 25979327 [TBL] [Abstract][Full Text] [Related]
55. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. John M; Constien R; Akinc A; Goldberg M; Moon YA; Spranger M; Hadwiger P; Soutschek J; Vornlocher HP; Manoharan M; Stoffel M; Langer R; Anderson DG; Horton JD; Koteliansky V; Bumcrot D Nature; 2007 Oct; 449(7163):745-7. PubMed ID: 17898712 [TBL] [Abstract][Full Text] [Related]
56. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo. Torres A; Kozak J; Korolczuk A; Rycak D; Wdowiak P; Maciejewski R; Torres K Oncotarget; 2016 Nov; 7(45):73651-73663. PubMed ID: 27655663 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates. Gallo Cantafio ME; Nielsen BS; Mignogna C; Arbitrio M; Botta C; Frandsen NM; Rolfo C; Tagliaferri P; Tassone P; Di Martino MT Mol Ther Nucleic Acids; 2016 Jun; 5(6):. PubMed ID: 27327137 [TBL] [Abstract][Full Text] [Related]
58. TargetLink, a new method for identifying the endogenous target set of a specific microRNA in intact living cells. Xu Y; Chen Y; Li D; Liu Q; Xuan Z; Li WH RNA Biol; 2017 Feb; 14(2):259-274. PubMed ID: 27982722 [TBL] [Abstract][Full Text] [Related]